Table 1.
Effect of age in humoral response following Pfizer-BioNTech (mRNA BNT162b2) vaccine administration.
| Author | Country of origin | Sample size | Median age (range) | Measured immunoglobulin | % difference of means |
|---|---|---|---|---|---|
| Jabal et al. [10] | Israel | 514 | 57 y/o (30–60+) | Anti-S1/S2 IgG |
D21 IgG titer is 61% higher in <30 y/o vs. 30–39 y/o group IgG titer is 32% higher in <30 y/o vs. 40–49 y/o group IgG titer is 39% higher in <30 y/o vs. 50–59 y/o group IgG titer is 50% higher in <30 y/o vs. 60+ y/o group IgG titer is 19% higher in <30 y/o vs. 40–49 y/o group IgG titer is 23% higher in 30–39 y/o vs. 50–59 y/o group IgG titer is 41% higher in 30–39 y/o vs. 60+ y/o group IgG titer is 10% higher in 40–49 y/o vs. 50–59 y/o group IgG titer is 23% higher in 40–49 y/o vs. 60+ y/o group IgG titer is 19% higher in 50–59 y/o vs. 60+ y/o group |
| Naaber et al. [11] | Estonia | 118 | 34 y/o (21–68) | Anti-S-RBD IgG |
D21 IgG titer is 53% higher in <40 y/o vs. >40 y/o group D28 IgG titer is 26% higher in <40 y/o vs. >40 y/o group D63 IgG titer is 27% higher in <40 y/o vs. >40 y/o group |
| Salvagno et al. [12] | Italy | 925 | Mean age (range) Seropositive: 43 y/o (30–56) Seronegative: 44 y/o (31–57) |
Anti-S-RBD IgG |
D21 IgG titer is 84% higher in <60 y/o vs. ≥60 y/o group D50 IgG titer is 33% higher in <60 y/o vs. ≥60 y/o group |
| Ríos et al. [6] | Spain | 134 |
Total: 82.9 y/o (65–99) ≥80 y/o (n = 86) (ND) 65–79 y/o (n = 48) (ND) |
Anti-S IgG |
D43 IgG is 28% higher in ≥80 y/o vs. 65–79 y/o group |
| Pellini et al. [13] | Italy | 248 |
Total: 47 y/o (18–75) ≤37 y/o (n = 62) (ND) 37–47 y/o (n = 63) (ND) 47–56 y/o (n = 64) (ND) >56 y/o (n = 59) (ND) |
Anti-S1/S2 IgG |
D28 IgG titer is 27% higher in <37 y/o vs. 37–47 y/o group IgG titer is 47% higher in <37 y/o vs. 47–56 y/o group IgG titer is 60% higher in <37 y/o vs. >56 y/o group IgG titer is 28% higher in 37–47 y/o vs. 47–56 y/o group IgG titer is 45% higher in 37–47 y/o vs. >56 y/o group IgG titer is 24% higher in 47–56 y/o vs. >56 y/o group |
| Müller et al. [14] | Germany | 176 | Mean age (range) Younger group (<60 y/o, n=91): 42.2 y/o (19.5–59.5) Elderly group (>80 y/o, n=85): 87.9 y/o (80.1–100.5) |
Anti-S1 IgG |
D17–19 IgG is 87% higher in the younger vs. elderly group D38 IgG is 64% higher in the younger vs. elderly group |
| Frenck et al. [15] | 12–15 y/o group from United States 16–25 y/o group from other countries (Argentina, Brazil, Germany, South Africa, Turkey) |
3358 |
Received Pfizer Vaccine (n=1668) 12–15 y/o (n = 1131): 14 (12–15) 16–25 y/o (n = 537): 18 (16–25) Placebo (=1690) 12–15 y/o (n = 1129): 14 (12–15) 16–25 y/o (n = 561): 19 (16–25) |
Anti-SARS-CoV-2 serum neutralization assay |
D49 In those without evidence of infection, neutralizing titer is 43% higher in the 12–15 y/o vs. 16–25 y/o group In all participants who received Pfizer vaccine, regardless of serologic evidence of previous infection, neutralizing titer is 43% higher in the 12–15 y/o vs. 16–25 y/o group In all participants who received placebo, regardless of serologic evidence of previous infection, neutralizing titer is 29% higher in the 12–15 y/o vs. 16–25 y/o group |